Yes, Continue Biktarvy and Discontinue Pifeltro
For a virologically suppressed adult with HIV on Biktarvy after recent jaw lymphoma excision, you should absolutely continue Biktarvy as monotherapy and discontinue Pifeltro (doravirine). Biktarvy is a complete three-drug regimen that is FDA-approved as a standalone treatment for HIV-1 infection in virologically suppressed patients 1, while adding Pifeltro creates unnecessary polypharmacy with no clinical benefit.
Why This Is the Correct Decision
Biktarvy Is a Complete Regimen
Biktarvy contains three active antiretroviral agents: bictegravir (integrase inhibitor), emtricitabine, and tenofovir alafenamide 1. This single-tablet regimen is specifically indicated to replace the current antiretroviral regimen in those who are virologically suppressed 1. It requires no additional antiretroviral agents.
Pifeltro Adds Nothing But Risk
Doravirine (Pifeltro) is an NNRTI that has no documented drug-drug interactions with bictegravir 2. However, combining these agents:
- Creates unnecessary pill burden
- Increases cost without benefit
- Potentially increases adverse event risk
- Violates standard HIV treatment principles
The 2025 IAS-USA guidelines emphasize that bictegravir-based regimens have a high barrier to resistance and are recommended for maintaining virologic suppression 3. There is no indication for adding a fourth antiretroviral drug in a virologically suppressed patient.
Real-World Evidence Supports Biktarvy Monotherapy
Multiple recent studies demonstrate excellent outcomes with Biktarvy alone in virologically suppressed patients:
- 98% maintained virologic suppression at 12 months when switched to Biktarvy in a large real-world cohort (n=799) with high comorbidity burden 4
- Virological failure occurred in only 4.2% in clinical practice, with 75% achieving re-suppression while maintaining Biktarvy 5
- Treatment durability was excellent with discontinuation rates of only 15-17% over 24-30 months, mostly for simplification rather than failure 5, 6
Post-Lymphoma Considerations
After jaw lymphoma excision, key priorities include:
- Maintaining virologic suppression to prevent immune deterioration
- Minimizing drug-drug interactions with potential future chemotherapy or supportive medications
- Simplifying the regimen to improve adherence during cancer follow-up
Biktarvy has favorable interaction profiles with cancer treatments 3, and the single-tablet regimen optimizes adherence. Adding Pifeltro complicates this unnecessarily.
Common Pitfall to Avoid
Do not assume that "more drugs = better control." In virologically suppressed patients, adding unnecessary antiretrovirals increases toxicity risk without improving efficacy. The patient is already on a guideline-recommended, high-barrier-to-resistance regimen 3.
Monitoring After Discontinuing Pifeltro
After stopping Pifeltro:
- Check HIV RNA at 4-8 weeks to confirm continued suppression
- Monitor CD4 count (though note that Biktarvy may cause modest CD4 decreases of ~76 cells/μL without clinical significance 7)
- Assess for any drug-drug interactions if new medications are added for cancer follow-up
The evidence unequivocally supports continuing Biktarvy alone and discontinuing the redundant Pifeltro.